T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

被引：0
|
作者：
K Mihara
J Bhattacharyya
A Kitanaka
K Yanagihara
T Kubo
Y Takei
H Asaoku
Y Takihara
A Kimura
机构：
[1] Research Institute for Radiation Biology and Medicine,Department of Hematology and Oncology
[2] Hiroshima University,Department of Laboratory Medicine
[3] Faculty of Medicine,Department of Life Science
[4] Kagawa University,Department of Biochemistry
[5] Yasuda Women’s University Faculty of Pharmacy,Department of Clinical Laboratory
[6] Nagoya University Graduate School of Medicine,Department of Stem Cell Biology
[7] Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital,undefined
[8] Research Institute for Radiation Biology and Medicine,undefined
[9] Hiroshima University,undefined
来源：
Leukemia | 2012年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：365 / 367
页数：2
相关论文
共 50 条
  • [31] Chimeric antigen receptor T-cell therapy for multiple myeloma
    Hosen, Naoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (04) : 530 - 534
  • [32] Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma
    Atrash, Shebli
    Ali, Syed Abbas
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (01): : 21 - 34
  • [33] Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
    Hernandez, Inmaculada
    Prasad, Vinay
    Gellad, Walid F.
    JAMA ONCOLOGY, 2018, 4 (07) : 994 - 996
  • [34] Development of chimeric antigen receptor (CAR) T-cell immunotherapy
    Borchmann, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 27 - 27
  • [35] Chimeric antigen receptor T-cell therapy for multiple myeloma
    Naoki Hosen
    International Journal of Hematology, 2020, 111 : 530 - 534
  • [36] Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
    Navab, Rahul
    Futela, Pragyat
    Kumari, Verkha
    Valecha, Jayesh
    Gupta, Ramansh Bandhu
    Jain, Rohit
    IRANIAN JOURNAL OF MEDICAL SCIENCES, 2025, 50 (01) : 1 - 10
  • [37] Targeting CD38 on exhausted T cells overcomes resistance to cancer immunotherapy
    Revach, Or-Yam
    Cicerchia, Angelina M.
    Sade-Feldman, Moshe
    Anderson, Seth
    Manguso, Robert T.
    Hacohen, Nir
    Jenkins, Russell W.
    CANCER RESEARCH, 2023, 83 (07)
  • [38] Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
    Poels, Renee
    Drent, Esther
    Lameris, Roeland
    Katsarou, Afroditi
    Themeli, Maria
    van der Vliet, Hans J.
    de Gruijl, Tanja D.
    van de Donk, Niels W. C. J.
    Mutis, Tuna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (03) : 1 - 16
  • [39] EVALUATION OF CD38 AS TARGET FOR IMMUNOTHERAPY IN MULTIPLE-MYELOMA - RESPONSE
    GOLDMACHER, VS
    LAMBERT, JM
    ANDERSON, KC
    BLOOD, 1995, 85 (08) : 2283 - 2284
  • [40] Efficient Targeting of CD38 in Mature T-Cell Neoplasms with Daratumumab and Allogeneic NK Cells
    Johnson, William T.
    Isabelle, Colleen
    Vogel, Ashley N.
    Brammer, Jonathan E.
    Boles, Amy E.
    McConnell, Kathleen
    Berge, Robyn
    Nisenfeld, Liam
    Uppal, Guldeep
    Gong, Jerald
    Chakravarti, Nitin
    Porcu, Pierluigi
    Mishra, Anjali
    BLOOD, 2021, 138
12345